According to the Associated Press, Johnson & Johnson and three drug distributors will settle thousands of opioid lawsuits nationwide at a price of $26 billion.
Two people familiar with the main settlement agreement chose to remain anonymous because they had no right to comment and confirmed the plan to the Associated Press. The settlement also involves drug distributors AmerisourceBergen, Cardinal Health and McKesson, and is expected to be the largest single settlement to date against the opioid epidemic in the United States. Johnson & Johnson said in a statement that it is ready to invest up to $5 billion in this huge settlement.
Johnson & Johnson said: “We continue to make progress in finalizing the agreement, and we remain committed to providing certainty to all parties involved and providing critical assistance to families and communities in need.” “Reconciliation is not an admission of responsibility or misconduct. The company will Continue to defend any litigation that is not resolved by the final agreement.”
Since 2000, more than 500,000 deaths in the United States have been related to prescription opioids and illegal opioids (such as heroin and fentanyl). An Associated Press analysis showed that the transportation of prescription opioids in 2012 could have provided every U.S. citizen with a 20-day supply.
For more reports from the Associated Press, please see below:
David Benito/Getty Images
As a prelude to a larger transaction, New York on Tuesday reached an agreement with distribution companies AmerisourceBergen, Cardinal Health and McKesson to address the state’s ongoing trials. This transaction alone will generate more than $1 billion in revenue to mitigate the damage caused by opioids there. The trial is expected to continue, but the settlement agreement leaves only three drugmakers as defendants.
New York State Attorney General Letia James said in a statement Tuesday: “Today, we hold them responsible for providing more than $1 billion in funding to New York communities ravaged by opioids for treatment, rehabilitation and prevention. jobs.”
Those who provided the Associated Press with details of the national settlement did so on the condition of anonymity because they had no right to speak when the details were finalized.
The national settlement will not end the case, but it will change the case. In addition to the deals being pursued by OxyContin manufacturer Purdue Pharma and generic drug manufacturer Mallinckrodt, after Johnson & Johnson’s settlement, the three major manufacturers will no longer participate in the case, and national drug distributors will no longer participate.
Other manufacturers, regional distribution companies and pharmacies will remain in these cases for now.
Cardinal Health declined to comment earlier on Tuesday, and other distribution companies did not respond to requests for comment. Johnson & Johnson reached a settlement with New York just before the New York trial began last month.
Distribution companies face thousands of similar legal claims from state and local governments across the country, and have long tried to resolve all these issues. If it can be reached this year, the New York deal will become part of a nationwide agreement.
State and local governments have stated that distribution companies do not have appropriate controls to mark or stop shipments to pharmacies that receive a large number of powerful and addictive prescription pain relievers. These companies insist that they are filling out legal drug orders placed by doctors-so they should not be held responsible for the country’s drug addiction and overdose crisis.
According to the New York settlement agreement, the three companies will provide more than $1 billion to slow the epidemic in the state. The money will be paid in 18 years, and the first payment will be made this year.
These companies will also establish a national data exchange on the distribution of opioids, and the data will be monitored by an independent agency. Johnson & Johnson also agreed not to produce any opioids in the next 10 years.
Including the New York case, three trials are currently being conducted across the United States against government entities claiming that the company is responsible for the opioid crisis. The one in California is specifically for drugmakers, and the one planned to end in West Virginia this month is only for distributors. If an agreement is reached, this may end.
Other cases are queued to start. So far, the only incident in which a verdict has been issued has occurred in Oklahoma two years ago. There, a judge ordered Johnson & Johnson to pay $465 million. Johnson & Johnson was the only company that did not settle before the trial. The company is appealing the verdict.
The New York case is by far the most widely heard case, and it is also the first case to be decided by a jury rather than just by a judge.
Johnson & Johnson settled with 230 million U.S. dollars before the start of the case. The remaining defendants are Teva Pharmaceuticals, Endo International and AbbVie.
With so many cases approaching trial, a series of opioid proposals or solutions have emerged. Purdue Pharma, the manufacturer of OxyContin, declared bankruptcy as part of its efforts to resolve the case. As part of the company’s approximately US$10 billion transaction, the company proposed a reorganization that will use all future profits to fight the epidemic. The plan will face some opposition at a confirmation hearing in the U.S. Bankruptcy Court next month.
